# Prime Medicine, Inc. (PRME)

Informational only - not investment advice.

CIK: 0001894562
SIC: 2836 Biological Products, (No Diagnostic Substances)
SIC breadcrumb: [Manufacturing](/division/D/) > [Chemicals And Allied Products](/major-group/28/) > [SIC 2836 Biological Products, (No Diagnostic Substances)](/industry/2836/)
Latest 10-K filed: 2026-03-03
SEC page: https://www.sec.gov/edgar/browse/?CIK=1894562
Filing source: https://www.sec.gov/Archives/edgar/data/1894562/000162828026013569/prme-20251231.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-03-03 · accession 0001628280-26-013569 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001894562.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 4,632,000 USD | 2025 | verified |
| Net income | -201,142,000 USD | 2025 | verified |
| Assets | 342,733,000 USD | 2025 | verified |
| Free cash flow | -167,095,000 USD | 2025 | computed |
| Revenue YoY | +55.28% | 2025 | computed |
| ROE | -166.41% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | PRME | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | -65.5% | -14.7% | 25 | 33 |
| Operating margin | -17.9% | -16.8% | 48 | 32 |
| Revenue growth | 55.3% | 20.9% | 68 | 42 |
| FCF margin | -3,607.4% | -127.6% | 14 | 43 |
| ROE | -166.4% | -38.7% | 10 | 60 |
| ROA | -58.7% | -30.4% | 17 | 66 |
| Liabilities / equity | 1.84 | 0.38 | 85 | 62 |
| Current ratio | 4.84 | 5.52 | 42 | 66 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 2836 Biological Products, (No Diagnostic Substances), not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 4632000 | USD | 2025 | 2026-03-03 |
| Net income | -201142000 | USD | 2025 | 2026-03-03 |
| Assets | 342733000 | USD | 2025 | 2026-03-03 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-03-03. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001894562.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue |  | 5,210,000 |  |  |  | 2,983,000 | 4,632,000 |
| Net income |  | -3,410,000 | -165,367,000 | -121,821,000 | -198,133,000 | -195,882,000 | -201,142,000 |
| Operating income |  | -932,000 | -84,474,000 | -116,544,000 | -204,792,000 | -202,467,000 | -208,350,000 |
| Diluted EPS |  | -1.91 | -14.19 | -4.19 | -2.18 | -1.65 | -1.35 |
| Operating cash flow |  | -5,544,000 | -34,082,000 | -131,827,000 | -165,412,000 | -122,865,000 | -162,564,000 |
| Capital expenditures |  | 639,000 | 4,150,000 | 16,095,000 | 8,724,000 | 7,294,000 | 4,531,000 |
| Assets |  |  | 301,856,000 | 360,314,000 | 193,851,000 | 297,508,000 | 342,733,000 |
| Liabilities |  |  | 62,296,000 | 44,044,000 | 60,780,000 | 144,359,000 | 221,865,000 |
| Stockholders' equity | -2,598,000 | 2,338,000 | -156,240,000 | 316,270,000 | 133,071,000 | 153,149,000 | 120,868,000 |
| Cash and cash equivalents |  | 36,975,000 | 185,420,000 | 187,620,000 | 41,574,000 | 182,476,000 | 63,032,000 |
| Free cash flow |  | -6,183,000 | -38,232,000 | -147,922,000 | -174,136,000 | -130,159,000 | -167,095,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin |  | -65.45% |  |  |  |  |  |
| Operating margin |  | -17.89% |  |  |  |  |  |
| Return on equity |  | -145.85% |  | -38.52% | -148.89% | -127.90% | -166.41% |
| Return on assets |  |  | -54.78% | -33.81% | -102.21% | -65.84% | -58.69% |
| Liabilities / equity |  |  |  | 0.14 | 0.46 | 0.94 | 1.84 |
| Current ratio |  |  | 4.67 | 11.10 | 2.53 | 5.58 | 4.84 |

## As-reported value updates

No tracked differences above grepcent's stated thresholds and capped precision rule were found between the earliest XBRL-filed value and the value currently on file for the standardized annual metrics grepcent tracks.


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-06. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001894562.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q3 | 2022-09-30 |  |  | -1.61 | reported discrete quarter |
| 2023-Q1 | 2023-03-31 |  |  | -0.44 | reported discrete quarter |
| 2023-Q2 | 2023-06-30 |  |  | -0.47 | reported discrete quarter |
| 2023-Q3 | 2023-09-30 |  | -50,708,000 | -0.55 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 |  | -65,643,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 | 591,000 | -45,761,000 | -0.44 | reported discrete quarter |
| 2024-Q2 | 2024-06-30 | 0.00 | -55,327,000 | -0.46 | reported discrete quarter |
| 2024-Q3 | 2024-09-30 | 209,000 | -52,518,000 | -0.44 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 2,183,000 | -42,276,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 | 1,454,000 | -51,890,000 | -0.40 | reported discrete quarter |
| 2025-Q2 | 2025-06-30 | 1,115,000 | -52,591,000 | -0.41 | reported discrete quarter |
| 2025-Q3 | 2025-09-30 | 1,225,000 | -50,582,000 | -0.32 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 838,000 | -46,079,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 |  | -49,122,000 | -0.28 | reported discrete quarter |
| 2026-Q2 | 2026-06-30 |  | -42,109,000 | -0.24 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from PRME's latest 10-K: [/company/PRME/business/](/company/PRME/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from PRME's latest 10-K: [/company/PRME/risk-factors/](/company/PRME/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/1894562/000162828026053883/prme-20260630.htm

Extracted from a later financial-section MD&A body after Item 2 boundaries were low-confidence.
Confidence: high
Filing date: 2026-08-06
Report date: 2026-06-30

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 3, 2026. As discussed in the section titled “Special Note Regarding Forward-Looking Statements,” the following discussion and analysis contains forward-looking statements that involve risks and uncertainties, such as statements regarding our plans, objectives, expectations, intentions, or projections, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2025. Our historical results are not necessarily indicative of the results that may be expected for any period in the future.

Overview

We are a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression.

We are advancing our in vivo programs to cure two of the largest genetic liver diseases, Wilson disease and AATD. In June 2026, we received clearance of the CTA for PM577a, an investigational Prime Editor for Wilson disease, in New Zealand, representing the first clinical authorization for one of our in vivo Prime Editing therapies and enabling the initiation of our global Phase 1/2 clinical trial. In July 2026, the FDA cleared our IND application for PM577a. The IND clearance opens participation in our global Phase 1/2 clinical trial to patients in the United States, where H1069Q is the single most common pathogenic variant causing Wilson disease. Additionally, we are on track for IND application submission and/or CTA filing in the third quarter of 2026 for PM647 in AATD. We intend to leverage the modularity of our platform to expeditiously and efficiently develop these programs supported by our universal liver lipid nanoparticle along with potential regulatory, clinical and other synergies from our modular technology.

We also continue to advance our in vivo Cystic Fibrosis program with support from Cystic Fibrosis Foundation and our efforts to develop Prime Edited CAR-T products for hematology, immunology, and oncology in partnership with BMS. In addition, we will continue to pursue additional business development opportunities to accelerate innovation, ensure the broadest application of Prime Editing, and further bolster our financial resources.

In August 2025, we announced additional data from the first patient dosed and initial data from the second patient dosed in our Phase 1/2 trial in CGD. We continue to engage in regulatory dialogue with the FDA toward a Biologics License Application submission for PM359, which is planned for the first half of 2027. In June 2026, the FDA granted RMAT designation for PM359, which provides opportunities for intensive FDA guidance and potential expedited review during the program’s development.

Components of Our Results of Operations

Revenues

To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products for the foreseeable future. Our revenues to date have been generated through research collaboration and license agreements. We recognize revenue over the expected performance period under each agreement. We expect that our revenue for the next several years will be derived primarily from our current collaboration agreements and any additional collaborations that we may enter into in the future. To date, we have not received any royalties under any of our existing collaboration agreements.

22

Research and Development Expenses

Research and development expenses consist primarily of costs incurred in connection with the development and research of our immediate target indications and our differentiation target indications. These expenses include:

•personnel-related expenses, including salaries, bonuses, benefits and stock-based compensation for employees engaged in manufacturing, and research and development functions;

•expenses incurred in connection with continuing our current research programs and preclinical and clinical development of any product candidates we may identify, including under agreements with third parties, such as consultants and contractors;

•the cost of developing and validating our manufacturing process for use in our preclinical and clinical studies;

•laboratory supplies and research materials;

•facilities, depreciation and other expenses related to research and development activities, which include direct or allocated expenses for rent and maintenance of facilities, and utilities;

•the cost allocated to acquire in-process research and development, with no alternative future use associated with asset acquisitions or transactions to license intellectual property, such as our Broad License Agreement; and

•expenses incurred in connection with our Pledge to Broad Institute.

We expense all research and development costs in the periods in which they are incurred. Most of our research and development expenses have been related to early stage development activities. In the future, external research and development costs for any individual product candidate will be tracked commencing upon product candidate nomination. We do not allocate employee costs, costs associated with our discovery efforts, laboratory supplies, and facilities expenses, including depreciation or other indirect costs, to specific product development programs because these costs are deployed across multiple programs and our platform and, as such, are not separately classified.

Upfront and milestone payments made are accrued for and expensed when the achievement of the milestone is probable up to the point of regulatory approval. Milestone payments made upon regulatory approval will be capitalized and amortized over the remaining useful life of the related product.

We expect our research and development expenses may continue to increase in the future with our planned research and development activities related to developing any future product candidates, including investments in manufacturing, as we advance any product candidates we may identify and begin to conduct clinical trials, and with our obligations under the BMS Collaboration Agreement.

General and Administrative Expenses

General and administrative expenses consist of salaries and personnel-related costs, including stock-based compensation, for our personnel in executive, legal, finance and accounting, human resources and other administrative functions. General and administrative expenses also include legal fees relating to patents and corporate matters; professional fees paid for accounting, auditing, consulting and tax service; insurance costs; office and information technology costs; and facilities, depreciation and other general and administrative expenses, which include direct or allocated expenses for rent and maintenance of facilities and utilities.

We anticipate that our general and administrative expenses will increase in the future if we increase our headcount to support research and development activities; increased accounting, legal, insurance, and investor and public relations costs as we continue to operate as a public company; and additional intellectual property-related expenses as we file patent applications to protect innovations arising from our research and development activities.

23

Other Income (Expense)

Other income (expense), net primarily consists of interest and amortization related to our short-term investments.

Results of Operations

Comparison of the Three Months Ended June 30, 2026 and 2025

Operating Expenses

Research and Development Expenses

[[GREPCENT_TABLE]]
[["","","Three Months Ended June 30,"],["(in thousands)","","2026","","2025","","Change"],["Research and development expenses:"],["Personnel expenses","","$","10,800","","","$","14,448","","","$","(3,648)"],["Facility related","","10,577","","","13,765","","","(3,188)"],["Research costs","","6,158","","","8,116","","","(1,958)"],["Clinical expenses","","2,102","","","574","","","1,528"],["Professional and consultant fees","","2,010","","","1,660","","","350"],["License, intellectual property fees, and other","","1,750","","","2,812","","","(1,062)"],["Total research and development expenses","","$","33,397","","","$","41,375","","","$","(7,978)"]]
[[/GREPCENT_TABLE]]

The $8.0 million decrease in research and development expenses for the three months ended June 30, 2026 as compared to the three months ended June 30, 2025 was primarily driven by:

•$3.6 million decrease in personnel expenses, driven primarily by fewer personnel-related costs resulting from the workforce reduction announced in May 2025;

•$3.2 million decrease in facility costs primarily related to cost savings realized from bringing our vivarium in-house;

•$2.0 million decrease in research costs as we advance our in vivo liver franchise from research towards IND application submission and potential clinical trials; and

•$1.1 million decrease in license and IP costs primarily due to license fees recognized in the second quarter of 2025.

These were offset by a $1.5 million increase in clinical expenses as we advance our Wilson disease and AATD programs.

General and Administrative Expenses

[[GREPCENT_TABLE]]
[["","","Three Months Ended June 30,"],["(in thousands)","","2026","","2025","","Change"],["General and administrative expenses:"],["Personnel expenses","","$","5,559","","","$","7,082","","","$","(1,523)"],["Facility related and other","","2,983","","","2,079","","","904"],["Professional and consultant fees","","2,500","","","3,956","","","(1,456)"],["Total general and administrative expenses","","$","11,042","","","$","13,117","","","(2,075)"]]
[[/GREPCENT_TABLE]]

24

The $2.1 million decrease in general and administrative expenses for the three months ended June 30, 2026 as compared to the three months ended June 30, 2025 was primarily driven by:

•$1.5 million decrease in personnel expenses, driven primarily by fewer personnel-related costs resulting from the workforce reduction announced in May 2025 and a decrease in stock compensation expense of $0.8 million; and

•$1.5 million decrease in professional and consultant fees primarily related to lower corporate legal fees.

Other Income (Expense)

[[GREPCENT_TABLE]]
[["","","Three Months Ended June 30,"],["(in thousands)","","2026","","2025","","Change"],["Other income:"],["Interest income","","$","788","","","$","743","","","$","45"],["Accretion (amortization) of investments","","333","","","530","","","(197)"],["Change in fair value of short-term investment \u2014 related party","","\u2014","","","(505)","","","505"],["Other income, net","","55","","","18","","","37"],["Total other income, net","","$","1,176","","","$","786","","","$","390"]]
[[/GREPCENT_TABLE]]

Comparison of the Six Months Ended June 30, 2026 and 2025

Operating Expenses

Research and Development Expenses

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/1894562/000162828026013569/prme-20251231.htm
Complete FY 2025 MD&A: /company/PRME/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary.
Confidence: high
Filing date: 2026-03-03
Report date: 2025-12-31

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review "Item 1A, Risk Factors" of this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

We are a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression.

We are focused on advancing our in vivo liver franchise, where we are advancing programs to cure two of the largest genetic liver diseases, Wilson Disease and AATD. Both programs are currently in late stages of pre-clinical development and are on track for IND and/or CTA filings in the first half of 2026 for Wilson Disease and the middle of 2026 for AATD. We intend to leverage the modularity of our platform to expeditiously and efficiently develop these programs supported by our universal liver lipid nanoparticle along with potential regulatory, clinical and other synergies from our modular technology.

We also continue to advance our in vivo Cystic Fibrosis program with support from CFF, and our efforts to develop Prime Edited CAR-T products for hematology, immunology and oncology in partnership with BMS. In addition, we will continue to pursue additional business development opportunities to accelerate innovation, ensure the broadest application of Prime Editing, and further bolster our financial resources.

In August 2025, we announced additional data from the first patient dosed and initial data from the second patient dosed in our Phase 1/2 trial in CGD. Discussions are underway with the FDA to explore a potential accelerated path to approval in the United States.

Components of Our Results of Operations

Revenues

To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products for the foreseeable future. Our revenues to date have been generated through research collaboration and license agreements. We recognize revenue over the expected performance period under each agreement. We expect that our revenue for the next several years will be derived primarily from our current collaboration agreements and any additional collaborations that we may enter into in the future. To date, we have not received any royalties under any of our existing collaboration agreements.

Research and Development Expenses

Research and development expenses consist primarily of costs incurred in connection with the development and research of our immediate target indications and our differentiation target indications. These expenses include:

•personnel-related expenses, including salaries, bonuses, benefits and stock-based compensation for employees engaged in manufacturing, and research and development functions;

•expenses incurred in connection with continuing our current research programs and preclinical and clinical development of any product candidates we may identify, including under agreements with third parties, such as consultants and contractors;

•the cost of developing and validating our manufacturing process for use in our preclinical and clinical studies;

114

•laboratory supplies and research materials;

•facilities, depreciation and other expenses related to research and development activities, which include direct or allocated expenses for rent and maintenance of facilities, and utilities;

•the cost allocated to acquire in-process research and development, with no alternative future use associated with asset acquisitions or transactions to license intellectual property, such as our Broad License Agreement; and

•expenses incurred in connection with our Pledge to Broad Institute.

We expense all research and development costs in the periods in which they are incurred. Most of our research and development expenses have been related to early stage development activities. In the future, external research and development costs for any individual product candidate will be tracked commencing upon product candidate nomination. We do not allocate employee costs, costs associated with our discovery efforts, laboratory supplies, and facilities expenses, including depreciation or other indirect costs, to specific product development programs because these costs are deployed across multiple programs and our platform and, as such, are not separately classified.

Upfront and milestone payments made are accrued for and expensed when the achievement of the milestone is probable up to the point of regulatory approval. Milestone payments made upon regulatory approval will be capitalized and amortized over the remaining useful life of the related product.

We expect our research and development expenses may continue to increase in the future with our planned research and development activities related to developing any future product candidates, including investments in manufacturing, as we advance any product candidates we may identify and begin to conduct clinical trials, and with our obligations under the BMS Collaboration Agreement.

General and Administrative Expenses

General and administrative expenses consist of salaries and personnel-related costs, including stock-based compensation, for our personnel in executive, legal, finance and accounting, human resources and other administrative functions. General and administrative expenses also include legal fees relating to patents and corporate matters; professional fees paid for accounting, auditing, consulting and tax service; insurance costs; office and information technology costs; and facilities, depreciation and other general and administrative expenses, which include direct or allocated expenses for rent and maintenance of facilities and utilities.

We anticipate that our general and administrative expenses will increase in the future if we increase our headcount to support research and development activities; increased accounting, legal, insurance, and investor and public relations costs as we continue to operate as a public company; and additional intellectual property-related expenses as we file patent applications to protect innovations arising from our research and development activities.

Other Income (Expense)

Other income (expense), net consists of:

•interest and amortization related to our short-term investments; and

•the change in the fair value of our short-term investment in Beam, a related party, in connection with the Beam Collaboration Agreement, which is discussed in greater detail in Item 1. Business, of this Annual Report on Form 10-K.

115

Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024

Operating Expenses

Research and Development Expenses

[[GREPCENT_TABLE]]
[["","","Year ended December 31,"],["(in thousands)","","2025","","2024","","Change"],["Research and development expenses:"],["Personnel expenses","","$","50,661","","","$","59,988","","","$","(9,327)"],["Research costs","","35,453","","","41,678","","","(6,225)"],["Facility related","","46,506","","","35,509","","","10,997"],["License, intellectual property fees, and other","","14,957","","","8,060","","","6,897"],["Professional and consultant fees","","7,681","","","5,919","","","1,762"],["Clinical expense","","5,378","","","4,135","","","1,243"],["Total research and development expenses","","$","160,636","","","$","155,289","","","$","5,347"]]
[[/GREPCENT_TABLE]]

The $5.3 million increase in research and development expense for the year ended December 31, 2025 as compared to the year ended December 31, 2024 is primarily driven by:

•$11.0 million increase in facility-related expense primarily due to the expansion and build out of our laboratory space at 60 First Street and 500 Arsenal Street and due to a higher amount of facility costs being allocated to our research and development function;

•$6.9 million increase in license and IP costs, primarily due to the issuance of restricted stock units;

•$1.8 million increase in professional and consultant fees, primarily related to our in-house vivarium; and

•$1.2 million increase in clinical expense as we advance our Wilson Disease and AATD programs, both of which are on track for IND and/or CTA filings in 2026.

These were offset by:

•$9.3 million decrease in personnel expenses resulting from the workforce reduction announced in May 2025; and

•$6.2 million decrease in research costs, primarily due to the deprioritization of our CGD programs as we strategically focus our internal efforts on advancing our in vivo liver franchise.

General and Administrative Expenses

[[GREPCENT_TABLE]]
[["","","Year ended December 31,"],["(in thousands)","","2025","","2024","","Change"],["General and administrative expenses:"],["Personnel expenses","","$","23,026","","","$","26,569","","","$","(3,543)"],["Professional and consultant fees","","20,500","","","13,459","","","7,041"],["Facility related and other","","8,820","","","10,133","","","(1,313)"],["Total general and administrative expenses","","$","52,346","","","$","50,161","","","$","2,185"]]
[[/GREPCENT_TABLE]]

116

The $2.2 million increase in general and administrative expense for the year ended December 31, 2025 as compared to the year ended December 31, 2024 is primarily driven by a $7.0 million increase in professional and consultant fees due to an increase in corporate legal expenses. This is offset by:

•$3.5 million decrease in personnel expense, due to a decrease in non-cash stock-based compensation expense of $3.5 million; and

•$1.3 million decrease in facility related and other primarily due to a higher proportion of our facility space being utilized in research and development activities.

Other Income (Expense)

[[GREPCENT_TABLE]]
[["","","Year ended December 31,"],["(in thousands)","","2025","","2024","","Change"],["Other income:"],["Interest income","","4,149","","","3,522","","","627"],["Accretion (amortization) of investments","","$","2,479","","","$","3,507","","","$","(1,028)"],["Change in fair value of short-term investment \u2014 related party","","432","","","(485)","","","917"],["Other income, net","","148","","","41","","","107"],["Total other income, net","","$","7,208","","","$","6,585","","","$","623"]]
[[/GREPCENT_TABLE]]

Accretion (amortization) of investments

Accretion (amortization) of investments for each of the periods presented is a result of increase (decrease) in the value of the our marketable securities purchased at a discount (premium) to their face value.

Liquidity and Capital Resources

Since our inception, we have incurred significant operating losses. We expect to incur significant expenses and operating losses for the foreseeable future as we commence the clinical development of our programs and continue our platform development and early-stage research activities. We have not yet commercialized any products and we do not expect to generate revenue from sales of products for several years, if at all. To date, we have funded our operations primarily with proceeds from sales of preferred stock, public offerings of our common stock, and through payments from our collaboration partners. As of December 31,

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/PRME/mda/fy2025/
All MD&A years: /company/PRME/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/PRME/mda/fy2024/): filed 2025-02-28; accession 0001628280-25-008884 (https://www.sec.gov/Archives/edgar/data/1894562/000162828025008884/prme-20241231.htm)
- [FY 2023 MD&A](/company/PRME/mda/fy2023/): filed 2024-03-01; accession 0001628280-24-008116 (https://www.sec.gov/Archives/edgar/data/1894562/000162828024008116/prme-20231231.htm)
- [FY 2022 MD&A](/company/PRME/mda/fy2022/): filed 2023-03-09; accession 0001628280-23-007266 (https://www.sec.gov/Archives/edgar/data/1894562/000162828023007266/prme-20221231.htm)


## FDA-approved drug applications

Applications listed under this company's exact-matched sponsor name. Approved applications only.

No resolved FDA applications were found for this company under the exact-unique, approved-only publish rule.

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

This list covers FDA applications whose listed sponsor name maps to this company by an exact-unique match; applications listed under sponsor names not mapped to this company (subsidiaries, name variants, joint ventures) are absent.


## Macro cross-references

Indicators mapped to this company's SIC classification (industry 2836 Biological Products, (No Diagnostic Substances)) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index
- [TCU](/indicator/TCU/): Capacity Utilization: Total Index
- [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity
- [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm

Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/PRME.md · JSON record: /company/PRME.json · verified financials: /company/PRME/financials.json / /company/PRME/financials.csv · machine TOC for the whole site: /llms.txt